Scholar Rock price target raised to $58 from $51 at BofA

BofA analyst Tazeen Ahmad raised the firm’s price target on Scholar Rock (SRRK) to $58 from $51 and keeps a Buy rating on the shares. Scholar Rock resubmitted its BLA for apitegromab in spinal muscular atrophy following FDA alignment at a March 3 Type C meeting, with two fill-finish partners included to address prior manufacturing concerns; a late-September PDUFA date is expected, supporting a revised U.S. launch timeline of 4Q26, the analyst tells investors in a research note. Dual manufacturing paths de-risk approval and enable launch readiness, though EU approval in mid-2026 remains contingent on Catalent Indiana clearance, while ongoing payer discussions aim to secure broad coverage beyond the Phase 3 SAPPHIRE criteria, the firm says.